Review Article

Severe Falciparum Malaria: An Overview

Khalid Abdelsamea Mohamedahmed^{1,2*}, Adam Dawoud Abakar³

¹Department of Hematology, Faculty of Medical Laboratory Science, University of Gezira, Wad Medani, Sudan

²Department of Immunology, Faculty of Medical Laboratory Science, University of Gezira, Wad Medani, Sudan

³Department of Medical Parasitology, Faculty of Medical Laboratory Science, University of Gezira, Wad Medani, Sudan

Malaria is a human intracellular protozoan parasitic disease caused by female anopheline mosquitoes inoculating plasmodium parasites on erythrocytes (1). Five types of *Plasmodium* are known to cause diseases in humans: *P. falciparum*, *P. vivax*, *P. malariae*, *P. ovale*, and *P. knowlesi* (2). Malaria is one of the leading causes of morbidity and death in the world, especially in Africa (3). In 2017, there were 219 million cases of malaria, responsible for 435 000 deaths worldwide. Malaria affects children aged 1–5 years the most, accounting for 61% (266 000) of all malaria deaths. In 2017, the WHO African Region had the highest number of malaria cases (200 million or 92%) and accounted for 93% of all malaria deaths. India and most countries in Sub-Saharan Africa bore nearly 80% of the global burden of the disease. *P. falciparum* is the most common malaria parasite in Africa (4).

Falciparum malaria is the most common malaria (5). In 2017, falciparum malaria accounted for 99.7% of malaria cases in Africa, 62.8% in South-East Asia, 69% in the Eastern Mediterranean Region, and 71.9% in the Western Pacific Region (4). Falciparum malaria is responsible for the vast majority of deaths (99%) (6).

Plasmodium falciparum is the most pathogenic type of human malaria parasite, and it is linked to acute parasitemia, which can lead to severe or complicated infection and death in infants, pregnant women, and non-immune individuals, as well as higher parasite burdens, and dysfunction of vital organs (7,8). If no effective therapy is administered promptly, mortality rates of about 25% and 30% will be expected in non-immune adults and non-immune infants, respectively (1).

Even though falciparum malaria is unrestricted to erythrocytes of a specific age, it is associated with the highest degree of parasite density. Falciparum malaria may also cause vascular obstruction which results from its ability to bind to endothelial cell walls. The majority of

the complications of *P. falciparum* infection occur due to this phenomenon (9).

The majority of malaria deaths occur due to Falciparum malaria. The infection of red blood cells (RBCs) with the mature plasmodium parasite results in the expression of parasite proteins, which is associated with their morphological structures (“knobs”) that permit them to bind to endothelial cells lining the blood vessels and lead to sequestration by vascular bed of vital organs of these infected RBCs. Cerebral malaria causes brain injury, which can lead to coma and death. Complications may involve the kidneys, lungs, and gastrointestinal tract. Stillbirth, low birth weight, and prenatal mortality are all possible outcomes of congenital malaria and placental infection. Repeated infections of erythrocytes by merozoites after the parasite initiates blood stage infection results in exponential development. As a result, the parasitized RBCs accumulate in capillaries and sinusoids, causing obstruction of peripheral blood circulation. Organomegaly, especially in the spleen and liver, is caused by congestion, which leads to anemia, leucopenia, and thrombocytopenia (7).

The severity of falciparum malaria is assessed by the presence of many factors such as the infective dose of the parasite, the host’s nutritional status, immune system status, growth rate of the parasite, genetic factors, socioeconomic status, antimalarial drug resistance status, access to health care, and education (10).

Coma, respiratory distress (pulmonary edema), bleeding, shock, intravascular hemolysis, jaundice, convulsions (clinical manifestations), severe anemia, hypoglycemia, Lactic (metabolic) acidosis, renal failure, and hyperparasitemia (laboratory features) are among the criteria recommended by the World Health Organization (WHO) for classifying severe malaria infections. Severe malaria is diagnosed based on the presence of two or more clinical or laboratory findings (12). Cerebral

Received: November 4, 2020, Accepted: December 3, 2020, ePublished: December 30, 2020

*Corresponding Author: Khalid Abdelsamea Mohamedahmed, Email: khalid.abdelsamea@hotmail.com

malaria, hemoglobinuria, hypotension, hematological changes (such as thrombocytopenia), hepatic instability, and cardiovascular failure are all correlated with severe falciparum malaria (2). Malaria caused by *P. falciparum* is associated with a mortality rate of 7%-32%, depending on the organs and systems involved (12).

Severe falciparum malaria is primarily a childhood disease in areas of the world where transmission of *P. falciparum* is intense and stable, and it is less frequent in adults and older children as unique adaptive immunity provides developed (though still incomplete) protection. Sub-Saharan Africa has the highest number of malaria cases, and 90% of the world's malaria-related deaths occur in this region (13).

We concluded that the falciparum malaria, especially its severe form, is one of the most common reasons for hospital admission and one of the most common causes of young children death in hospital in several endemic areas especially in sub-Saharan Africa. Finally, we recommended that severe falciparum malaria should be diagnosed using WHO criteria (presence of malaria parasitemia (+) and (++) did not roll out the severe malaria, and hyperparasitemia did not roll out the uncomplicated malaria).

Conflict of Interests

The authors have declared that no competing interests exist.

Ethical Issues

Not applicable.

Authors' Contributions

KAM developed the concepts, performed literature search, and prepared and edited the manuscript. ADA prepared and reviewed the article draft.

Funding

This study received no specific grant from any funding agency in the public, commercial or non-profit sectors.

References

1. Recker M, Bull PC, Buckee CO. Recent advances in the molecular epidemiology of clinical malaria. *F1000Res*. 2018;7. doi:10.12688/f1000research.14991.1
2. World Health Organization (WHO). *Guidelines for the Treatment of Malaria*. 3rd ed. Geneva: WHO; 2015.
3. Keiser J, Utzinger J, Caldas de Castro M, Smith TA, Tanner M, Singer BH. Urbanization in sub-Saharan Africa and implication for malaria control. *Am J Trop Med Hyg*. 2004;71(2 Suppl):118-127.
4. World Health Organization (WHO). *World Malaria Report 2018*. 11th ed. Geneva: WHO; 2018.
5. Mohamedahmed KA, Nour BY, Abakar AD, Babker AM. Diagnostic and prognostic value of thrombocytopenia severity in Sudanese children with Falciparum malaria. *World J Adv Res Rev*. 2020;6(3):197-204. doi:10.30574/wjarr.2020.6.3.0196
6. World Health Organization (WHO). *World Malaria Report 2016*. Geneva: WHO; 2016.
7. Satoskar AR, Simon G, Hotez PJ, Tsuji M. *Medical Parasitology*. USA: Landes Bioscience; 2009:240-241.
8. Mohamedahmed KA, Ahmed ZA, Nour BY, Abakar AD, Babker AM. Impact of severe *Plasmodium falciparum* infection on platelets parameters among Sudanese children living in Al-Jazira state. *Int J Clin Biomed Res*. 2020;6(2):5-9. doi:10.31878/ijcbr.2020.62.02
9. Cheesbrough M. *District Laboratory Practice in Tropical Countries, Part 1*. 2nd ed. London: Cambridge University Press; 2006:240-242.
10. Phillips RS. Current status of malaria and potential for control. *Clin Microbiol Rev*. 2001;14(1):208-226. doi:10.1128/cmr.14.1.208-226.2001
11. World Health Organization (WHO). *Basic Malaria Microscopy*. 2nd ed. Geneva: WHO; 2010.
12. Kinra P, Dutta V. Serum TNF alpha levels: a prognostic marker for assessment of severity of malaria. *Trop Biomed*. 2013;30(4):645-653.
13. Black RE, Cousens S, Johnson HL, et al. Global, regional, and national causes of child mortality in 2008: a systematic analysis. *Lancet*. 2010;375(9730):1969-1987. doi:10.1016/S0140-6736(10)60549-1